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OBJECTIVEdChronic exposure to calcineurin inhibitors and corticosteroids poses renal
transplant recipients (RTR) at high risk for development of new-onset diabetes after transplan-
tation (NODAT). Pancreaticb-cell dysfunctionmay be crucial to the pathophysiology of NODAT
and speciﬁcmarkers forb-cell dysfunctionmay have additive value for predicting NODAT in this
population. Therefore, we prospectively investigated whether proinsulin, as a marker of pan-
creatic b-cell dysfunction, is associated with future development of NODAT and improves pre-
diction of it.
RESEARCH DESIGN ANDMETHODSdAll RTR between 2001 and 2003 with a func-
tioning graft for$1 year were considered eligible for inclusion, except for subjects with diabetes
at baseline who were excluded. We recorded incidence of NODAT until April 2012.
RESULTSdA total of 487 RTR (age 506 12 years, 55%men) participated at a median time of
6.0 (interquartile range [IQR], 2.6–11.5) years after transplantation. Median fasting proinsulin
levels were 16.6 (IQR, 11.0–24.2) pmol/L. During median follow-up for 10.1 (IQR, 9.1–10.4)
years, 42 (35%) RTR had development of NODAT in the highest quartile of the distribution of
proinsulin versus 34 (9%) in the lowest three quartiles (P, 0.001). In Cox regression analyses,
proinsulin (hazard ratio, 2.29; 95% CI, 1.85–2.83; P , 0.001) was strongly associated with
NODAT development. This was independent of age, sex, calcineurine inhibitors, prednisolone
use, components of the metabolic syndrome, or homeostasis model assessment.
CONCLUSIONSdIn conclusion, fasting proinsulin is strongly associated with NODAT de-
velopment in RTR. Our results highlight the role of b-cell dysfunction in the pathophysiology of
NODAT and indicate the potential value of proinsulin for identiﬁcation of RTR at increased risk
for NODAT.
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New-onset diabetes after transplan-tation (NODAT) is one of the mainmetabolic complications of renal
transplantation (1). It is estimated to af-
fect ;20% of renal transplant recipients
(RTR) (2). NODAT places RTR at an in-
creased risk for infections, cardiovascular
disease, graft failure, and mortality (2–4).
Comparable with type 2 diabetes, NODAT
may be a result of increased insulin resis-
tance and decreased insulin production by
the pancreatic b-cell (5). Early identiﬁca-
tion of increased risk for NODAT,
allowing for early intervention, could be
of great importance to renal transplant
health care considering the detrimental
effects associated with NODAT.
The presence of pretransplantation
insulin resistance in the ﬁnal stage of
kidney failure is seen as a mechanism in
the development of NODAT (6). The
chronic exposure to calcineurin inhibi-
tors and corticosteroids aggravates the in-
sulin resistance and poses RTR at high
risk for NODAT development (7,8). An-
other potential mechanism inNODAT is a
defect in insulin secretion as a conse-
quence of pancreatic b-cell dysfunction,
leading to an inability to compensate for
insulin resistance (5,6).
As a precursor of insulin, intact
proinsulin has been proposed as a spe-
ciﬁc marker of b-cell dysfunction (5). In
the past, nonspeciﬁc assays showed
high cross-reactivity that could lead to
incorrect conclusions on b-cell dys-
function and prediction of diabetes.
A new, speciﬁc, intact proinsulin ELISA
(no cross-reactivity) has been developed
that can be easily used in routine labo-
ratories (9).
It is unknown whether proinsulin is a
good marker of b-cell dysfunction in RTR
and whether it is independently associ-
ated with future development of NODAT
or if it predicts NODAT beyond estab-
lished clinical risk predictors. Therefore,
we prospectively investigated the associ-
ation between b-cell dysfunction, insulin
resistance, and NODAT development
in RTR. Furthermore, we investigated
whether proinsulin had additive value in




Study design and inclusion/exclusion cri-
teria have been described previously (10).
In brief, for this prospective cohort study all
adult allograft recipients between August
2001 and July 2003 who survived with a
functioning allograft beyond the ﬁrst year
after transplantation were eligible to partic-
ipate at their next visit to our outpatient
clinic. A total of 606 from an eligible 847
RTR (72% consent rate) signed written in-
formed consent. We excluded 105 recipi-
ents with existing diabetes (deﬁned as
fasting plasma glucose$7.0 or antidiabetic
medication) at baseline from analysis. Pro-
insulin levels were available in 487 RTR,
leaving 487 nondiabetic RTR for analysis.
Baseline data were collected between Au-
gust 2001 and July 2003, and RTR were
followed-up for several years. The Institu-
tional Review Board approved the study
protocol (METc 2001/039).
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Renal transplant characteristics
The Groningen Renal Transplant Data-
base contains information on all renal
transplantations performed at our center
since 1968. Relevant transplant recipient
characteristics such as age, sex, and date
of transplantation were extracted from
this database. We found current medica-
tion information in the medical record
and obtained information on employ-
ment status, living situation, smoking
and alcohol consumption, and cardiovas-
cular history by self-report questionnaire.
Standard immunosuppressive treat-
ment consisted of the following: prednis-
olone and azathioprine (100 mg/day)
from 1968 to 1989; cyclosporine stan-
dard formulation (trough levels of 175 to
200 mg/L in the ﬁrst 3 months, 150 mg/L
between 3 and 12 months after trans-
plantation, and 100 mg/L thereafter;
Sandimmune; Novartis Pharma B.V.,
Arnhem, the Netherlands) and predniso-
lone (starting with 20 mg/day, rapidly ta-
pered to 10 mg/day) from January 1989
to February 1993; cyclosporine microe-
mulsion (trough levels idem; Neoral;
Novartis Pharma B.V.) and prednisolone
fromMarch 1993 to May 1997; and myco-
phenolate mofetil (2 g/day; Cellcept; Roche
B.V., Woerden, the Netherlands), which
was added from May 1997 to present
date. In some speciﬁc situations, immu-
nosuppressive medication deviated from
the standard protocol. Cyclosporine was
converted to tacrolimus in the event of
acute rejection, hypertrichosis, gingival
hypertrophy, or intolerance of cyclospor-
ine. Target trough levels of tacrolimus
were 6 to 10 mg/L. Sirolimus was used
when frequent skin malignancy occurred.
Target trough levels of sirolimus were 4 to
6.5 mg/L.
Measurements and deﬁnitions
BMI was determined as a measure of
overall obesity. BMI was calculated as
weight in kilograms divided by height in
meters squared. Waist circumference was
measured on bare skin midway between
the iliac crest and the 10th rib. Muscle
mass was estimated by 24-h creatinine
excretion as described previously (11).
Blood pressure was measured after a
6-min rest in the supine position as the
average of three automated measure-
ments at 1-min intervals (Omron M4;
Omron Europe B.V.).
Blood was drawn after an overnight
fasting period. Plasma glucose, insulin,
HDL cholesterol, LDL cholesterol,
high-sensitivity C-reactive protein,
and serum creatinine were measured as
described previously (10). Homeostasis
model assessment (HOMA) was calculated
as: [glucose (mmol/L)3 insulin (in micro-
units/mL)]/22.5 (12). In this study, me-
tabolic syndrome (MS) was deﬁned
according to the deﬁnition of the Na-
tional Cholesterol Education Program
Expert Panel (NCEP-ATPIII) (13).
Proinsulin. Proinsulin levels were mea-
sured with the Mercodia-Proinsulin
ELISA. Mercodia-Proinsulin ELISA is a
solid phase, two-site enzyme immunoas-
say based on the sandwich technique, in
which two monoclonal antibodies are
directed against separate antigenic de-
terminants on the proinsulin molecule.
Proinsulin in the sample reacts with anti-
proinsulin antibodies bound to microti-
tration wells and peroxidase-conjugated
anti-insulin antibodies in the solution.
Cross-reactivity for insulin is ,0.03%
and cross-reactivity for C-peptide is
,0.006%.
NODAT. The International Expert Panel
Meeting (14) proposed recommendations
to deﬁne NODAT based on the American
Diabetes Association criteria 2003 (15).
The diagnosis of NODAT was based on
one of the following criteria: symptoms
of diabetes (classic symptoms of diabetes
include polyuria, polydipsia, and un-
explained weight loss) plus casual plasma
glucose concentration$200 mg/dL (11.1
mmol/L); fasting plasma glucose $126
mg/dL (7.0 mmol/L); or use of antidia-
betic medication. Fasting is deﬁned as
no caloric intake for at least 8 h. NODAT
was recorded until April 2012.
Statistical analyses
Data were analyzed with SPSS version
16.0 (SPSS, Chicago, IL), STATA version
11 (StataCorp LP), and GraphPad Prism
version 4.03 (GraphPad Software, San
Diego, CA). Recipient-related characteris-
tics were analyzed separately for quartiles
of proinsulin. For analyses, we combined
quartiles 1–3 as one group and compared
this group with quartile 4. Differences
between groups were tested for statisti-
cal signiﬁcance with Student t test for
normally distributed variables, Mann-
Whitney test for skewed distributed
variables, and x2 test for categorical var-
iables.We performedmultivariate Cox re-
gression analyses to investigate whether
proinsulin is independently associated
with NODAT. In subsequent multivariate
analyses, we investigated whether the as-
sociation of proinsulin is independent of
age, sex, use of cyclosporine, tacrolimus,
dose of prednisolone, trough levels of
cyclosporine and tacrolimus, HOMA, or
components of the metabolic syndrome.
Death was regarded as a competing risk
for NODAT. Patients were censored at
date of last follow-up or death.
Because there are no validated clinical
models for the prediction of NODAT in
RTR, we used a commonly used predic-
tion model for the general population.
This clinical model includes the follow-
ing: sex, smoking, waist circumference,
hypertension, and family history of di-
abetes (16). To assess the added value of
proinsulin, we examined improvement of
diabetes prediction in terms of discrimi-
nation and integrated discrimination im-
provement (IDI). Discrimination was
evaluated using the Harrell c-index for
censored data, a statistic similar to the
area under a receiver-operating character-
istic curve (17). In general, discrimination
refers to the ability of a model to distin-
guish well between individuals with and
without incident diabetes; a value of 1
implies a perfect discrimination and a
value of 0.5 implies performance no better
than chance. We used IDI as a continuous
measure of reclassiﬁcation, calculated by
subtracting the mean difference of pre-
dicted risk between the clinical model
(16) and the model including different
biomarkers.
RESULTSdThe study cohort was com-
posed of 487 RTR (55% men) aged 50 6
12 years at a median time of 6.0 (inter-
quartile range, 2.6–11.5) years after trans-
plantation. Median concentration of
fasting proinsulin was 16.6 (interquartile
range, 11.0–24.2) pmol/L. Baseline char-
acteristics of the RTR according to the
two groups of proinsulin are shown in
Table 1. RTR with high proinsulin (quar-
tile 4 versus quartiles 1–3) were more
obese, with higher BMI and waist circum-
ference. High proinsulin was positively
associated with use of b-blocker, use of
statin, history of BMI, high-sensitivity
C-reactive protein, glucose, insulin,
HOMA, and proinsulin-to-insulin ratio.
RTR with high proinsulin had signiﬁ-
cantly lower creatinine clearance and
higher serum creatinine. We found other
differences in lipid-proﬁle with lower
HDL and LDL cholesterol and higher tri-
glycerides in subjects with high proinsu-
lin. There was a trend toward lower use of
tacrolimus in subjects with high proinsu-
lin. No differences were found in other
components of immunosuppressive
treatment. Out of the 487 RTR, 309
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Table 1dRecipient characteristics according to groups of proinsulin
Quartiles of proinsulin
1–3 (N = 366) 4 (N = 121) P
General characteristics
Age (years) 50.4 6 12.5 51.1 6 11.0 0.6
Male sex, n (%) 203 (55.5) 68 (56.2) 0.9
Lifestyle
Physical activity (METS) 124.5 (31.2–312.1) 118.7 (26.7–294.1) 0.4
MS, n (%) 208 (57) 101 (86) ,0.001
Smoking, n (%) 150 (41.3) 48 (39.7) 0.8
Alcohol consumption
Abstain, n (%) 160 (44) 63 (53)
0.2
,10 g/day, n (%) 145 (40) 44 (37)
10–30 g/day, n (%) 52 (14) 13 (11)
.30 g/day, n (%) 6 (2) 0 (0)
Body composition
BMI (kg/m2) 25.1 6 3.9 27.8 6 4.2 ,0.001
Waist circumference (cm), women 90.4 6 13.3 98.8 6 13.8 ,0.001
Waist circumference (cm), men 96.6 6 11.1 105.7 6 10.9 ,0.001
Urinary creatinine excretion (mmol/24 h) 11.9 (9.5–14.4) 11.9 (9.8–13.9) 0.9
Blood pressure
Systolic pressure (mmHg) 152.0 6 23.1 149.6 6 20.9 0.3
Diastolic pressure (mmHg) 90.0 6 10.1 89.3 6 9.3 0.5
Use of ACE inhibitor or angiotensin II antagonist, n (%) 117 (32) 49 (40.5) 0.09
Use of b-blocker, n (%) 216 (59.0) 87 (71.9) 0.01
History of cardiovascular disease
Myocardial infarction, n (%) 24 (6.6) 16 (13.2) 0.02
Transient ischemic attack/cerebrovascular accident, n (%) 12 (3.4) 8 (6.6) 0.1
Inﬂammation
High-sensitivity C-reactive protein (mg/L) 1.8 (0.7–4.3) 2.8 (1.2–5.9) 0.007
Lipids
Total cholesterol (mmol/L) 5.7 6 1.1 5.6 6 1.0 0.2
LDL (mmol/L) 3.7 6 1.0 3.4 6 0.9 0.007
HDL (mmol/L) 1.1 6 0.3 1.0 6 0.7 ,0.001
Triglycerides (mmol/L) 1.8 (1.3–2.4) 2.4 (1.7–3.2) ,0.001
Use of statin at index, n (%) 165 (45.1) 71 (58.7) 0.009
Glucose homeostasis
Glucose (mmol/L) 4.5 6 0.6 4.8 6 0.8 ,0.001
Insulin (mmol/L) 9.4 (7.0–12.4) 15.0 (11.1–21.1) ,0.001
HOMA 1.81 (1.29–2.52) 3.28 (2.31–4.39) ,0.001
Proinsulin (pmol/L) 13.8 (9.6–17.9) 36.4 (28.4–51.5) ,0.001
Proinsulin/insulin ratio 1.4 (1.0–1.9) 2.6 (1.7–3.4) ,0.001
Family history of diabetes: parent or
sibling with diabetes, n (%) 86 (23) 32 (26) 0.5
Renal allograft function
Serum creatinine concentration (mmol/L) 134.0 (111.8–163.3) 146.0 (123.0–174.0) 0.007
Urinary creatinine excretion 11.9 (9.5–14.4) 11.9 (9.8–13.9) 1.0
Creatinine clearance (mL/min) 60.0 (47.0–78.0) 57.0 (43.0–71.5) 0.04
Urinary protein excretion (g/24 h) 0.2 (0.0–0.5) 0.3 (0.1–0.5) 0.1
Proteinuria, n (%) 98 (26.8) 36 (29.8) 0.5
Transplantation and history
Number of transplantations .1, n (%) 39 (10.7) 12 (9.9) 0.2
Time after transplantation (years) 6.4 (2.9–12.2) 5.7 (2.2–12.2) 0.8
Dialysis duration (months) 26 (12–49) 33 (19–49) 0.06
Immunosuppression
Calcineurine inhibitor, n (%) 286 (78.1) 93 (76.9) 0.8
Cyclosporine, n (%) 234 (61.6) 82 (67.8) 0.3
Continued on p. 1929
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Proinsulin levels predict NODAT in RTR
(75%) fulﬁlled the criteria for MS. Preva-
lence of MS was 101 (86%) in the highest
quartile of proinsulin compared with 208
(57%) in the lowest three quartiles (P ,
0.001).
NODAT developed during median
follow-up for 10.1 (interquartile range,
9.7–10.4) years in 76 (16%) RTR. Inci-
dence of NODAT was 42 (35%) in the
highest quartile compared with 34 (9%)
in the lowest three quartiles of proinsulin
(P, 0.001) (Fig. 1). Cumulative percen-
tages of NODAT at 1, 3, 5, and 10 years
after baseline were 1.2, 4.6, 7.4 and
14.8%, respectively.
Subsequently, we proceeded with
prospective analyses for proinsulin and
development of NODAT during follow-
up. Proinsulin (hazard ratio [HR], 2.29;
95% CI, 1.85–2.83; P , 0.001) strongly
predicted NODAT development in RTR
in univariate analyses. Multivariate Cox
regression analyses for proinsulin and
NODAT development are shown in Table
2. Adjustment for age and sex did not ma-
terially inﬂuence the associations (model
2). We adjusted for use of cyclosporine,
tacrolimus, and prednisolone dose in
model 3. This adjustment also did not
materially inﬂuence the association of
proinsulin with NODAT development.
Of note, use of tacrolimus was signiﬁ-
cantly associated with NODAT develop-
ment (HR, 2.84; 95% CI, 1.37–5.89; P =
0.005) in this Cox regression model. This
was independent of proinsulin, age, sex,
use of cyclosporine, and prednisolone
dose. We found no signiﬁcant association
of use of cyclosporine with development
of NODAT. In further analyses in which
we additionally adjusted for trough levels
of tacrolimus and cyclosporine (model 4),
we found no additional association of
trough levels of tacrolimus with NODAT.
However, trough levels of cyclosporine
were associated with increased risk for
higher concentrations (HR, 1.07; 95%
CI, 1.01–1.13; P = 0.02). In further anal-
yses, it appeared that the association be-
tween proinsulin and NODAT was
independent of HOMA (model 5). Inter-
estingly, in thismodel, HR for HOMA also
was associated with NODAT independent
of proinsulin (HR, 1.23; 95% CI, 1.09–
1.40; P = 0.001). Adjustments for factors
of MS (model 6) slightly weakened the
association, but proinsulin remained in-
dependently associated with NODAT.
Waist circumference (HR, 1.02; 95% CI,
1.01–1.04; P = 0.01), triglycerides (HR,
1.21; 95% CI, 1.05–1.40; P = 0.01), and
glucose (HR, 2.26; 95% CI, 1.63–3.11;
P , 0.001) were signiﬁcantly associated
with NODAT, independent of proinsulin.
Evaluation of prognostic value of pro-
insulin is summarized in Table 3. Harrell
c-index of discrimination improved from
0.71 (interquartile range, 0.65–0.77) to
0.80 (interquartile range, 0.75–0.85 [see
Table 3]; P , 0.01) after adding
proinsulin to a clinical prediction model
including sex, smoking, waist circumfer-
ence, hypertension, and family history of
diabetes (16). IDI analysis shows that
the clinical risk score with proinsulin pre-
dicted NODAT more accurately than the
clinical risk score alone.We found similar
results when HOMA or glucose was
added to the clinical model. When pro-
insulin was added on top of glucose, IDI
was positive and remained signiﬁcant.
These results show that proinsulin is aprom-
ising biomarker for predicting NODAT
beyond established clinical risk predic-
tors in RTR.
CONCLUSIONSdOur study shows
that proinsulin is an independent pre-
dictor of NODAT in RTR. Proinsulin
levels predicted development of NODAT
in RTR after adjustment for risk factors for
NODAT. Our ﬁndings emphasize the
importance of b-cell dysfunction in the
pathophysiology of NODAT in RTR.
In our study, adjustment for MS
(waist circumference, triglycerides, HDL
cholesterol, blood pressure, and glucose
concentration) attenuated the association
of proinsulin with NODAT. This supports
the notion that MS and particularly waist
circumference, triglycerides, and glucose,
partly contribute to this association. Fac-
tors of the MS could be modiﬁed by
regular physical activity and a healthy
diet, which shows the importance of
lifestyle interventions after renal trans-
plantation. The association between pro-
insulin and NODAT was independent of
HOMA, which suggests that the relation-
ship is driven by b-cell dysfunction.
It has become clear that both insulin
resistance and b-cell dysfunction
are present early in the natural history
of diabetes. There is a hyperbolic
Table 1dContinued
Quartiles of proinsulin
1–3 (N = 366) 4 (N = 121) P
Cyclosporine (trough level, mg/L) 108 (80–138) 104 (77–149) 0.9
Tacrolimus, n (%) 57 (15.6) 11(9.1) 0.07
Tacrolimus (trough level, mg/L) 8.7 (6.4–10.2) 8.6 (6.0–9.7) 0.9
Proliferation inhibitor, n (%) 278 (87) 72 (72) 0.4
Azathioprine, n (%) 124 (33.9) 38 (31.4 0.6
Mycophenolate mofetil, n (%) 154 (42.1) 49 (40.5) 0.8
Sirolimus, n (%) 8 (2.2) 2 (1.7) 0.7
Sirolimus (trough level, mg/L) 9.0 6 4.9 7.3 6 6.3 0.7
Prednisolone dose (mg/day) 9.1 6 1.4 9.3 6 1.3 0.3
Data are represented as mean6 SD or median (95%CI). Differences were tested by ANOVA or Kruskal-Wallis test for continuous variables and with x2 for categorical
variables.
Figure 1dKaplan-Meier curve of de novo di-
abetes in quartiles of proinsulin tested with log-
rank test (P < 0.001). Cut-off points for
quartiles of proinsulin were as follows: quar-
tiles 1–3, 2.4–24.4 (pmol/L), and quartile 4,
.24.5 (pmol/L).
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relationship between insulin sensitivity
and insulin secretion that depends on a
negative feedback loop. Pancreatic
b-cells compensate for changes in insu-
lin sensitivity (18,19). In healthy sub-
jects, plasma glucose levels are
maintained near to normal, even with
low insulin sensitivity, as a consequence
of a compensatory increase in insulin se-
cretion. RTR are more insulin-resistant
than the general population. Oterdoom
et al. (20) showed that obesity, waist-to-
hip ratio, and prednisolone treatment
are the predominant determinants of in-
sulin resistance after transplantation.
Furthermore, proinsulin can be used
as a marker of pancreatic b-cell dysfunc-
tion. In this light, increased circulating
levels of proinsulin are seen as a marker
of b-cell stress when insulin demands
required for maintenance of glycemic
control are relatively high for the
prevailing b-cell capacity. This is accom-
panied by increased “spill-over” of pro-
insulin (5).
Calcineurin inhibitors impair insulin
secretion, produce b-cell toxicity, cause
insulin resistance, and thereby contribute
to an increased risk for NODAT (21–23).
Various studies comparing cyclosporine
and tacrolimus showed that use of cyclo-
sporine is associated with a signiﬁcantly
lower incidence ofNODAT than tacrolimus
after renal transplantation (3,8,24). Inter-
estingly, proinsulin levels tended to be
lower in RTR receiving tacrolimus, de-
spite the fact that use of tacrolimus was
signiﬁcantly associated with increased
risk for NODAT development. Use of ta-
crolimus increased the risk for NODAT
by almost three-fold (HR, 2.84; 95% CI,
1.37–5.89; P = 0.005). This observation
could point to the known interference of
tacrolimus with insulin production by
pancreatic b-cells at the level of synthesis
rather than at the level of conversion of
proinsulin to insulin (21–23). The low
variation in steroid doses in the popula-
tion we investigated did not allow for us
to ﬁnd a relationship between steroid
dose and NODAT.
Based on the results from the United
Kingdom Prospective Diabetes Study, it
was suggested that b-cell dysfunction was
reduced up to 50% at time of diagnosis
(25). Loss of b-cell dysfunction starts
many years before diagnosis. Therefore,
proinsulin can be used to identify patients
at risk for NODAT development several
years later. Elevated levels of proinsulin
can be present despite normal glucose
values. Proinsulin can still bind to the in-
sulin receptor and has a glucose-lowering
effect of 10–20% compared with insulin
(26). Because of this minor but evident
effect, patients with b-cell dysfunction
do not always have diabetes diagnosed.
Although no cut-off points for proinsulin
are described in the literature, there is one
study in which cut-off values are given for
deﬁning insulin resistance. Data from the
IRIS-II (study on insulin resistance and
insulin sensitivity) show that elevated
proinsulin levels (.10 pmpl/L) are a
good indirect marker for insulin resis-
tance (27). In our study, 80% of the
RTR had proinsulin levels above this
threshold of .10 pmpl/L. This may re-
ﬂect the fact that b-cell function is im-
paired in almost all RTR because of
increased metabolic demands on the
b-cells and the chronic exposure to im-
munosuppressive drugs, which places
RTR at high risk for development of
NODAT (2).
Sharif et al. (28) validated important
insulin resistance indexes in RTR using
tacrolimus. Rodrigo et al. (29) analyzed
the performance of two general popula-
tion risk scores for prediction of diabetes
in RTR. None of these three evaluations
included a marker of b-cell dysfunction.
Chakkera et al. (30) recently developed a
pretransplant risk score for the prediction
of post-transplant diabetes. Also, in this
study, no marker of b-cell dysfunction
was included. The performance of the
risk score developed by Chakkera et al.
(30) was modest, with areas under receiver-
operating curves varying between 0.70 and
0.72. Our study is the ﬁrst to include a
marker of b-cell dysfunction in addition
to insulin resistance indexes in the pre-
diction of NODAT in RTR. In our analy-
ses, we found that both proinsulin as a
marker of b-cell dysfunction and
HOMA as a marker for insulin resistance
are independently associated with in-
creased risk for NODAT. The prediction
model with proinsulin had good discrim-
ination, showing that 80% of the RTR
were adequately classiﬁed as at risk for
NODAT. Integrated discrimination im-
proved by 8% by adding proinsulin to
the model. Proinsulin is a promising
marker for early detection of patients at
risk for NODAT and, possibly, future
studies also may identify it as useful in
the clinic to monitor b-cell function early
after transplantation. Monitoring b-cell
functions could allow for early interven-
tion and treatment strategies to preserve
b-cell function. Interestingly, Hecking
et al. (31) recently showed in a random-
ized controlled study that basal insulin
therapy may be a good strategy to reduce
HbA1c and may decrease the incidence of
NODAT, presumably by protection of the
b-cells. Patients were randomized to im-
mediate postoperative isophane insulin
(treatment group) or short-acting insulin




model HR (95% CI) P
1 2.29 (1.85–2.83) ,0.001
2 2.26 (1.83–2.81) ,0.001
3 2.43 (1.94–3.04) ,0.001
4 2.44 (1.95–3.04) ,0.001
5 1.76 (1.34–2.32) ,0.001
6 1.58 (1.25–1.99) ,0.001
Model 1, univariate analyses; model 2, model 1 +
adjustment for recipient age and sex; model 3,
model 2 + adjustment for cyclosporine, tacrolimus,
and prednisolone dose; model 4, model 3 + ad-
justment for trough levels of cyclosporine and ta-
crolimus; model 5, model 2 + adjustment HOMA;
model 6, model 2 + adjustment all components of
the MS (waist circumference, triglycerides, HDL
cholesterol, blood pressure, and glucose concen-
tration).




in C-statistic IDI P
Model 1 0.71 (0.65–0.77) d d d
Model 1 + proinsulin 0.80 (0.75–0.85) ,0.01 0.077 ,0.01
Model 1 + HOMA 0.77 (0.71–0.82) ,0.01 0.077 ,0.01
Model 1 + glucose 0.78 (0.73–0.84) ,0.01 0.075 (,0.01)
Model 1 + glucose and proinsulin 0.80 (0.75–0.85) 0.06 0.046 (,0.01)
Model 1 + proinsulin and glucose 0.80 (0.75–0.85) 0.06 0.038 (,0.01)
Model 1 uses clinicalmodel, including sex, smoking, waist circumference, hypertension, and family history of
diabetes.
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with or without oral antidiabetic agents
(standard care). The treatment group had
73% lower odds for NODAT and HbA1c
was 0.38% lower than in the control
group. Besides pharmacological strate-
gies, lifestyle interventions could play
an important role in prevention of NO-
DAT beyond the ﬁrst year after transplan-
tation. Exercise training decreases insulin
resistance and the risk of diabetes in the
general population, and it can be as-
sumed that it has similar effects in RTR.
Sharif et al. (32) showed that lifestyle
modiﬁcation is beneﬁcial for high-risk
RTR with glucose intolerance. Intensive
lifestyle modiﬁcation (dietitian, exercise
program, and weight loss advice) resulted
in 15% improvement in 2-h postprandial
glucose (32). Lifestyle interventions tar-
geting physical activity and diet after
transplantation as well as individualized
choice of immunosuppressive agents
could help in the prevention of NODAT.
The strength of our study is its pro-
spective design. RTR in this study were
closely monitored through regular check-
ups at our clinic, which provide complete
information on patient status. Our study
population is a cross-cut of all the RTR
who visited our outpatient clinic, giving a
variation of RTR with different times after
transplantation and including stable RTR
late after transplantation. However, our
study is limited by the heterogeneousness
of our study population, with variable
time after transplantation and immuno-
suppressant medication. The healthy sur-
vivor effect is another drawback of our
study. We used multivariate Cox regres-
sion modeling to adjust for confounders
of NODAT. This modeling cannot fully
correct for the fact that RTR without
NODAT late after transplantation may
be a healthier group. Future studies could
investigate whether proinsulin levels
measured earlier after transplantation
also predict NODAT.
Proinsulin is strongly related to de-
velopment of NODAT in RTR.Our results
highlight the role of b-cell dysfunction
in the pathophysiology of NODAT in
RTR. Considering that the development
of NODAT is associated with a higher
risk of complications and worse survival,
identifying RTR at increased risk for de-
velopment of NODAT is needed. Proin-
sulin as a marker ofb-cell dysfunction has
potential value for identiﬁcation of RTR at
increased risk for NODAT. Prevention of
NODAT by lifestyle interventions, early
identiﬁcation of patients at risk, and
choice of immunosuppressivemedication
are all important to control and manage
NODAT in RTR.
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